Nanostructured delivery systems with improved leishmanicidal activity: a critical review

References

• BañulsALHideMPrugnolleFLeishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humansAdv Parasitol2007641–109455458
   Google Scholar
• SéguinODescoteauxALeishmania, the phagosome, and host responses: the journey of a parasiteCell Immunol20163091627531526
   PubMedGoogle Scholar
• MurrayHWBermanJDDaviesCRSaraviaNGAdvances in leishmaniasisLancet2005366949615611577
   PubMed Web of Science ®Google Scholar
• AlvarJVélezIDBernCLeishmaniasis worldwide and global estimates of its incidencePLoS One201275e3567122693548
   PubMed Web of Science ®Google Scholar
• LindgrenEAnderssonYSukJESudreBSemenzaJCPublic health: monitoring EU emerging infectious disease risk due to climate changeScience2012336608041841922539705
   PubMed Web of Science ®Google Scholar
• Van GriensvenJCarrilloELópez-VélezRLynenLMorenoJLeishmaniasis in immunosuppressed individualsClin Microbiol Infect201420428629924450618
   PubMed Web of Science ®Google Scholar
• HotezPJPecoulBRijalSEliminating the neglected tropical diseases: translational science and new technologiesPLoS Negl Trop Dis2016103e000389526934395
   PubMed Web of Science ®Google Scholar
• GustafsonHHHolt-CasperDGraingerDWGhandehariHNanoparticle uptake: the phagocyte problemNano Today201510448751026640510
   PubMed Web of Science ®Google Scholar
• GutiérrezVSeabraABRegueraRMKhandareJCalderónMNew approaches from nanomedicine for treating leishmaniasisChem Soc Rev201645115216826487097
   PubMed Web of Science ®Google Scholar
• AsthanaSGuptaPKChaurasiaMDubeAChourasiaMKPolymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargosExpert Opin Drug Deliv201310121633165124147603
   PubMed Web of Science ®Google Scholar
• SrivastavaSShankarPMishraJSinghSPossibilities and challenges for developing a successful vaccine for leishmaniasisParasit Vectors20169127727175732
   PubMed Web of Science ®Google Scholar
• BiswasSSubramanianAElmojtabaIMChattopadhyayJSarkarRROptimal combinations of control strategies and cost-effective analysis for visceral leishmaniasis disease transmissionPLoS One2017122e017246528222162
   PubMed Web of Science ®Google Scholar
• MeheusFBalasegaramMOlliaroPCost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinentPLoS Negl Trop Dis201049e81820838649
   PubMed Web of Science ®Google Scholar
• MeheusFAbuzaidAABaltussenRThe economic burden of visceral leishmaniasis in Sudan: an assessment of provider and household costsAm J Trop Med Hyg20138961146115324189368
   PubMed Web of Science ®Google Scholar
• TachfoutiNNajdiAAlonsoSCost of pediatric visceral leishmaniasis care in MoroccoPLoS One2016116e015548227257808
   PubMedGoogle Scholar
• UranwSMeheusFBaltussenRRijalSBoelaertMThe household costs of visceral leishmaniasis care in south-eastern NepalPLoS Negl Trop Dis201372e206223469298
   PubMed Web of Science ®Google Scholar
• Shaked-MishanPUlrichNEphrosMZilbersteinDNovel intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovaniJ Biol Chem200127663971397611110784
   PubMed Web of Science ®Google Scholar
• WalkerJSaraviaNGInhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agentJ Parasitol20049051155116215562618
   PubMedGoogle Scholar
• DemicheliCFrézardFLecouveyMGarnier-SuillerotAAntimony(V) complex formation with adenine nucleosides in aqueous solutionBiochim Biophys Acta20021570319219812020809
   PubMedGoogle Scholar
• JeddiFPiarrouxRMaryCAntimony resistance in Leishmania, focusing on experimental researchRe Dai Yi Xue Za Zhi20112011695382
   Google Scholar
• LeandroCCampinoLLeishmaniasis: efflux pumps and chemoresistanceInt J Antimicrob Agents200322335235713678842
   PubMedGoogle Scholar
• WalshTJGoodmanJLPappasPSafety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose studyAntimicrob Agents Chemother200145123487349611709329
   PubMed Web of Science ®Google Scholar
• BrajtburgJPowderlyWGKobayashiGSMedoffGAmphotericin B: current understanding of mechanisms of actionAntimicrob Agents Chemother19903421831882183713
   PubMed Web of Science ®Google Scholar
• OlliaroPLGuerinPJGerstlSHaaskjoldAARottingenJ-ASundarSTreatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004Lancet Infect Dis200551276377416310148
   PubMed Web of Science ®Google Scholar
• BalasegaramMRitmeijerKLimaMALiposomal amphotericin B as a treatment for human leishmaniasisExpert Opin Emerg Drugs201217449351023167833
   PubMed Web of Science ®Google Scholar
• SundarSChakravartyJAgarwalDRaiMMurrayHWSingle-dose liposomal amphotericin B for visceral leishmaniasis in IndiaN Engl J Med2010362650451220147716
   PubMed Web of Science ®Google Scholar
• SundarSChakravartyJAgarwalDShahAAgrawalNRaiMSafety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azarTrop Med Int Health20081391208121218664241
   PubMedGoogle Scholar
• SundarSPandeyKThakurCPEfficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label studyPLoS Negl Trop Dis201489e316925233346
   PubMedGoogle Scholar
• MbongoNLoiseauPMBillionMARobert-GeroMMechanism of amphotericin B resistance in Leishmania donovani promastigotesAntimicrob Agents Chemother19984223523579527785
   PubMed Web of Science ®Google Scholar
• PurkaitBKumarANandiNMechanism of amphotericin B resistance in clinical isolates of Leishmania donovaniAntimicrob Agents Chemother20125621031104122123699
   PubMed Web of Science ®Google Scholar
• ChawlaBJhingranAPanigrahiAStuartKDMadhubalaRParomomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin–susceptible–resistant Leishmania donovaniPLoS One2011610e2666022046323
   PubMed Web of Science ®Google Scholar
• SundarSChakravartyJParomomycin in the treatment of leishmaniasisExpert Opin Investig Drugs2008175787794
   PubMed Web of Science ®Google Scholar
• DorloTPCBalasegaramMBeijnenJHde VriesPJMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisJ Antimicrob Chemother201267112576259722833634
   PubMed Web of Science ®Google Scholar
• World-Health-OrganizationControl of the Leishmaniasis: Report of a Meeting of the WHO Expert Committee (N° 949) on the Control of LeishmaniasesGenevaWorld Health Organization2010
   Google Scholar
• LuxHHeiseNKlennerTHartDOpperdoesFREther-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in LeishmaniaMol Biochem Parasitol2000111111411087912
   PubMed Web of Science ®Google Scholar
• SundarSSinhaPJhaTKOral miltefosine for Indian post-kalaazar dermal leishmaniasis: a randomised trialTrop Med Int Health20131819610023136856
   PubMed Web of Science ®Google Scholar
• SrivastavaSMishraJGuptaAKSinghAShankarPSinghSLaboratory confirmed miltefosine resistant cases of visceral leishmaniasis from IndiaParasit Vectors20171014928137296
   PubMed Web of Science ®Google Scholar
• AlvarJGonzálezUPinartMInterventions for visceral leishmaniasisCochrane Database Syst Rev20106
   Google Scholar
• van GriensvenJBoelaertMCombination therapy for visceral leish-maniasisLancet2011377976444344421255829
   PubMed Web of Science ®Google Scholar
• SundarSSinhaPKRaiMComparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trialLancet2011377976447748621255828
   PubMed Web of Science ®Google Scholar
• WasunnaMNjengaSBalasegaramMEfficacy and safety of ambisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: phase II randomized trialPLoS Negl Trop Dis2016109e000488027627654
   PubMed Web of Science ®Google Scholar
• BarrettMPBoykinDWBrunRTidwellRRHuman African trypanosomiasis: pharmacological re-engagement with a neglected diseaseBr J Pharmacol200715281155117117618313
   PubMed Web of Science ®Google Scholar
• DiroERitmeijerKBoelaertMUse of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort studyPLoS Negl Trop Dis2015910e000408726431253
   PubMed Web of Science ®Google Scholar
• GeorgiadouSPStefosASpanakosGCurrent clinical, laboratory, and treatment outcome characteristics of visceral leishmaniasis: results from a seven-year retrospective study in GreeceInt J Infect Dis201534465025743761
   PubMedGoogle Scholar
• BasselinMCoombsGHBarrettMPPutrescine and spermidine transport in LeishmaniaMol Biochem Parasitol20001091374610924755
   PubMed Web of Science ®Google Scholar
• SinghGDeyCSInduction of apoptosis-like cell death by pentamidine and doxorubicin through differential inhibition of topoisomerase II in arsenite-resistant L. donovaniActa Trop2007103317218517655815
   PubMed Web of Science ®Google Scholar
• BasselinMDeniseHCoombsGHBarrettMPResistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrionAntimicrob Agents Chemother200246123731373812435669
   PubMed Web of Science ®Google Scholar
• WyllieSPattersonSStojanovskiLThe anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasisSci Transl Med20124119119re1
   PubMed Web of Science ®Google Scholar
• ThompsonAMO’ConnorPDBlaserARepositioning antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for neglected tropical diseases: structure–activity studies on a preclinical candidate for visceral leishmaniasisJ Med Chem20165962530255026901446
   PubMedGoogle Scholar
• GuptaSYardleyVVishwakarmaPNitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasisJ Antimicrob Chemother201570251852725389223
   PubMed Web of Science ®Google Scholar
• LuYAimettiAALangerRGuZBioresponsive materialsNat Rev Mater2016116075
   Web of Science ®Google Scholar
• JainKJainNKNovel therapeutic strategies for treatment of visceral leishmaniasisDrug Discov Today20131823–241272128123973338
   PubMed Web of Science ®Google Scholar
• ItaliaJLYahyaMMSinghDRavi KumarMNVBiodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous fungizone®Pharm Res20092661324133119214716
   PubMed Web of Science ®Google Scholar
• TorradoJJSerranoDRUchegbuIFThe oral delivery of amphotericin BTher Deliv20134191223401912
   PubMedGoogle Scholar
• TorradoJJEspadaRBallesterosMPTorrado-SantiagoSAmphotericin B formulations and drug targetingJ Pharm Sci20089772405242517893903
   PubMed Web of Science ®Google Scholar
• AllenTMCullisPRLiposomal drug delivery systems: from concept to clinical applicationsAdv Drug Deliv Rev2013651364823036225
   PubMed Web of Science ®Google Scholar
• LarabiMYardleyVLoiseauPMToxicity and antileishmanial activity of a new stable lipid suspension of amphotericin BAntimicrob Agents Chemother200347123774377914638481
   PubMed Web of Science ®Google Scholar
• MishraJDeyASinghNSomvanshiRSinghSEvaluation of toxicity and therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse modelIndian J Med Res2013137476777623703346
   PubMedGoogle Scholar
• AsadMBhattacharyaPBanerjeeAAliNTherapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin BBMC Infect Dis201515118825884796
   PubMed Web of Science ®Google Scholar
• ShadabMJhaBAsadMDeepthiMKamranMAliNApoptosis-like cell death in Leishmania donovani treated with KalsomeTM10, a new liposomal amphotericin BPLoS One2017122e017130628170432
   PubMedGoogle Scholar
• NewRRCChanceMLThomasSCPetersWAntileishmanial activity of antimonials entrapped in liposomesNature197827256485556203863
   PubMed Web of Science ®Google Scholar
• CarterKCDolanTFAlexanderJBaillieAJMcColganCVisceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c miceJ Pharm Pharmacol198941287912568434
   PubMedGoogle Scholar
• RoychoudhuryJSinhaRAliNTherapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c micePLoS One201163e1737621423750
   PubMed Web of Science ®Google Scholar
• ImmordinoMLDosioFCattelLStealth liposomes: review of the basic science, rationale, and clinical applications, existing and potentialInt J Nanomedicine20061329731517717971
   PubMed Web of Science ®Google Scholar
• AzevedoEGRibeiroRRda SilvaSMMixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasisExpert Opin Drug Deliv201411101551156024962630
   PubMed Web of Science ®Google Scholar
• ProulxM-EDésormeauxAMarquisJ-FOlivierMBergeronMGTreatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecinAntimicrob Agents Chemother20014592623262711502539
   PubMedGoogle Scholar
• KeighobadiMFakharMEmamiSHypothesis: the potential application of doxorubicin against cutaneous leishmaniasisTrop Parasitol201551697025709959
   PubMedGoogle Scholar
• AlvingCRDelivery of liposome-encapsulated drugs to macrophagesPharmacol Ther19832234074246361805
   PubMedGoogle Scholar
• JavedIHussainSZUllahISynthesis, characterization and evaluation of lecithin-based nanocarriers for the enhanced pharmacological and oral pharmacokinetic profile of amphotericin BJ Mater Chem B201534283598365
   PubMed Web of Science ®Google Scholar
• SapraPAllenTMLigand-targeted liposomal anticancer drugsProg Lipid Res200342543946212814645
   PubMed Web of Science ®Google Scholar
• AgrawalAKAgrawalAPalAGuruPYGuptaCMSuperior chemotherapeutic efficacy of Amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamstersJ Drug Target2002101414511996085
   PubMed Web of Science ®Google Scholar
• Vázquez-MendozaACarreroJCRodriguez-SosaMParasitic infections: a role for C-type lectins receptorsBiomed Res Int2013201345635223509724
   PubMedGoogle Scholar
• RathoreAJainAGulbakeAMannosylated liposomes bearing amphotericin B for effective management of visceral leishmaniasisJ Liposome Res201121433334021612342
   PubMed Web of Science ®Google Scholar
• GuptaAEralHBHattonTADoylePSNanoemulsions: formation, properties and applicationsSoft Matter201612112826284126924445
   PubMed Web of Science ®Google Scholar
• WasanEKGershkovichPZhaoJA novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral leishmaniasis in a murine modelPLoS Negl Trop Dis201041216
   Google Scholar
• HnikPinventoriCo Therapeutics Inc., CanLaherty, Carol D, assigneeStable formulations for the oral administration of amphotericin BUS patentWO2016112339A120162016
   Google Scholar
• KansalSTandonRDwivediPDevelopment of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasisJ Antimicrob Chemother201267112650266022872448
   PubMed Web of Science ®Google Scholar
• ShingithaKPA review: niosomes a novel tool for drug deliveryInt J Pharm Technol20156330173026
   Google Scholar
• BaillieAJCoombsGHDolanTFLaurieJNon-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconateJ Pharm Pharmacol19863875025052875149
   PubMed Web of Science ®Google Scholar
• KhazaeliPSharifiITalebianEHeraviGMoazeniEMostafaviMAnti-leishmanial effect of itraconazole niosome on in vitro susceptibility of Leishmania tropicaEnviron Toxicol Pharmacol201438120521124956400
   PubMedGoogle Scholar
• SalernoCChiappettaDAMonteagudoEBregniCInfluence of surfactant structure in the encapsulation and stability of amphotericin B in niosomesLatin Am J Pharm201130917281736
   Google Scholar
• ZarifLDrug delivery by lipid cochleatesMethods Enzymol200539131432915721389
   PubMed Web of Science ®Google Scholar
• SesanaAMMonti-RochaRVinhasSAMoraisCGDietzeRLemosEMIn vitro activity of amphotericin B cochleates against Leishmania chagasiMem Inst Oswaldo Cruz2011106225125321537689
   PubMedGoogle Scholar
• ManninoRJinventorBiodelivery Sciences International, Inc., USA, assigneePharmaceutical cochleate compositions comprising amphotericin B for treating leishmaniasisUS patentWO2010091090A120102010
   Google Scholar
• PhamTTBarrattGMichelJPLoiseauPMSaint-Pierre-ChazaletMInteractions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin B-miltefosine-loaded nanocochleatesColloids Surf B Biointerfaces201310622423323434716
   PubMed Web of Science ®Google Scholar
• BattagliaLGallarateMLipid nanoparticles: state of the art, new preparation methods and challenges in drug deliveryExpert Opin Drug Deliv20129549750822439808
   PubMed Web of Science ®Google Scholar
• JainVGuptaAPawarVKChitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticlesAppl Biochem Biotechnol201417441309133025106894
   PubMed Web of Science ®Google Scholar
• Heidari-KharajiMTaheriTDoroudDHabibzadehSRafatiSSolid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice modelAppl Microbiol Biotechnol2016100167051706026960322
   PubMed Web of Science ®Google Scholar
• Heidari-KharajiMTaheriTDoroudDHabibzadehSBadirzadehARafatiSEnhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice modelParasite Immunol2016381059960827213964
   PubMed Web of Science ®Google Scholar
• VeerareddyPRVobalaboinaVAliNAntileishmanial activity, pharmacokinetics and tissue distribution studies of mannose-grafted amphotericin B lipid nanospheresJ Drug Target200917214014719089691
   PubMed Web of Science ®Google Scholar
• ChaudhariMBDesaiPPPatelPAPatravaleVBSolid lipid nanoparticles of amphotericin B (AmbiOnp): in vitro and in vivo assessment towards safe and effective oral treatment moduleDrug Deliv Transl Res20166435436426712123
   PubMed Web of Science ®Google Scholar
• da Gama BitencourtJJPazinWMItoASMiltefosine-loaded lipid nanoparticles: improving miltefosine stability and reducing its hemolytic potential toward erythtocytes and its cytotoxic effect on macrophagesBiophys Chem2016217203127497059
   PubMed Web of Science ®Google Scholar
• ElsabahyMWooleyKLDesign of polymeric nanoparticles for biomedical delivery applicationsChem Soc Rev20124172545256122334259
   PubMed Web of Science ®Google Scholar
• LiuZJiaoYWangYZhouCZhangZPolysaccharides-based nanoparticles as drug delivery systemsAdv Drug Deliv Rev200860151650166218848591
   PubMed Web of Science ®Google Scholar
• CouvreurPPuisieuxFNano- and microparticles for the delivery of polypeptides and proteinsAdv Drug Deliv Rev1993102141162
   Google Scholar
• MakadiaHKSiegelSJPoly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrierPolymers (Basel)2011331377139722577513
   PubMed Web of Science ®Google Scholar
• Van De VenHPaulussenCFeijensPBPLGA nanoparticles and nanosuspensions with amphotericin B: potent in vitro and in vivo alternatives to Fungizone and AmBisomeJ Control Release2012161379580322641062
   PubMed Web of Science ®Google Scholar
• ZhangZTanSFengS-SVitamin E TPGS as a molecular biomaterial for drug deliveryBiomaterials201233194889490622498300
   PubMed Web of Science ®Google Scholar
• ItaliaJLRavi KumarMNVCarterKCEvaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasisJ Biomed Nanotechnol20128469570222852479
   PubMed Web of Science ®Google Scholar
• AlsaadiMItaliaJLMullenABThe efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infectionJ Control Release2012160368569122516093
   PubMed Web of Science ®Google Scholar
• KumarRSahooGCPandeyKDevelopment of PLGA-PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasisMater Sci Eng C Mater Biol Appl20165974875326652429
   PubMed Web of Science ®Google Scholar
• AsthanaSJaiswalAKGuptaPKDubeAChourasiaMKTh-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid–polymer hybrid nanoparticle: biodistribution and toxicity assessment of encapsulated amphotericin BEur J Pharm Biopharm201589627325477079
   PubMed Web of Science ®Google Scholar
• NaharMJainNKPreparation, characterization and evaluation of targeting potential of amphotericin b-loaded engineered PLGA nanoparticlesPharm Res200926122588259819842021
   PubMed Web of Science ®Google Scholar
• BudhianASiegelSJWineyKIHaloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug contentInt J Pharm2007336236737517207944
   PubMed Web of Science ®Google Scholar
• BarrosDLimaSACCordeiro-Da-SilvaASurface functionalization of polymeric nanospheres modulates macrophage activation: relevance in leishmaniasis therapyNanomedicine201510338740325707974
   PubMedGoogle Scholar
• SinghPKSahPMeherJGMacrophage-targeted chitosan anchored PLGA nanoparticles bearing doxorubicin and amphotericin B against visceral leishmaniasisRSC Adv20166757170571718
   Web of Science ®Google Scholar
• AsthanaSGuptaPKJaiswalAKDubeAChourasiaMKTargeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studiesNanomedicine20151071093110925929567
   PubMed Web of Science ®Google Scholar
• SilvaTAbengózarMAFernandez-ReyesMEnhanced leishmanicidal activity of cryptopeptide chimeras from the active N1 domain of bovine lactoferrinAmino Acids20124362265227722543751
   PubMedGoogle Scholar
• KumarRSahooGCPandeyKDasVDasPStudy the effects of PLGA-PEG encapsulated Amphotericin B nanoparticle drug delivery system against Leishmania donovaniDrug Deliv201522338338824601828
   PubMed Web of Science ®Google Scholar
• PushpamalarJVeeramachineniAKOwhCLohXJBiodegradable polysaccharides for controlled drug deliveryChemPlusChem2016816504514
   PubMedGoogle Scholar
• SharmaGKarSBasu BallWGhoshKDasPKThe curative effect of fucoidan on visceral leishmaniasis is mediated by activation of MAP kinases through specific protein kinase C isoformsCell Mol Immunol201411326327424561457
   PubMed Web of Science ®Google Scholar
• Lehnhardt PiresCRodriguesSDBristotDEvaluation of macroalgae sulfated polysaccharides on the Leishmania (L.) amazonensis promastigoteMar Drugs201311393494323519148
   PubMedGoogle Scholar
• Kangussu-MarcolinoMMdo RosárioMMTNosedaMDAcid heteropolysaccharides with potent antileishmanial effectsInt J Biol Macromol20158116517026162246
   PubMed Web of Science ®Google Scholar
• MatteCMarquisJFBlanchetteJPeroxovanadium-mediated protection against murine leishmaniasis: role of the modulation of nitric oxideEur J Immunol20003092555256411009089
   PubMed Web of Science ®Google Scholar
• AmaralAEDPetkowiczCLOMercêALRLeishmanicidal activity of polysaccharides and their oxovanadium(IV/V) complexesEur J Med Chem20159073274125506811
   PubMedGoogle Scholar
• MachadoPAMotaVZCavalliACLHigh selective antileishmanial activity of vanadium complex with stilbene derivativeActa Trop201514812012725917716
   PubMedGoogle Scholar
• SingodiaDKharePDubeATalegaonkarSKharRKMishraPRDevelopment and performance evaluation of alginate-capped amphotericin B lipid nanoconstructs against visceral leishmaniasisJ Biomed Nanotechnol20117112312421485834
   PubMed Web of Science ®Google Scholar
• YangDJonesKSEffect of alginate on innate immune activation of macrophagesJ Biomed Mater Res A200990241141818523947
   PubMedGoogle Scholar
• PorporattoCBiancoIDRieraCMCorreaSGChitosan induces different L-arginine metabolic pathways in resting and inflammatory macrophagesBiochem Biophys Res Commun2003304226627212711309
   PubMedGoogle Scholar
• AsthanaSJaiswalAKGuptaPKPawarVKDubeAChourasiaMKImmunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsulesAntimicrob Agents Chemother20135741714172223357762
   PubMed Web of Science ®Google Scholar
• AsthanaSGuptaPKJaiswalAKDubeAChourasiaMKOverexpressed macrophage mannose receptor targeted nanocapsules-mediated cargo delivery approach for eradication of resident parasite: in vitro and in vivo studiesPharm Res20153282663267725715698
   PubMedGoogle Scholar
• RibeiroTGChávez-FumagallMAValadaresDGNovel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery systemInt J Nanomedicine20149187789024627630
   PubMedGoogle Scholar
• GuptaPKJaiswalAKKumarVCovalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluationMol Pharm201411395196324495144
   PubMedGoogle Scholar
• GuptaPKJaiswalAKAsthanaSSelf assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasisPharm Res20153251727174025425053
   PubMed Web of Science ®Google Scholar
• KansalSTandonRVermaACoating doxorubicin-loaded nanocapsules with alginate enhances therapeutic efficacy against Leishmania in hamsters by inducing Th1-type immune responsesBr J Pharmacol2014171174038405024837879
   PubMedGoogle Scholar
• LoiseauPMImbertieLBoriesCBetbederDDe MiguelIDesign and antileishmanial activity of amphotericin B-loaded stable Ionic Amphiphile Biovector formulationsAntimicrob Agents Chemother20024651597160111959611
   PubMed Web of Science ®Google Scholar
• MullenABCarterKCBaillieAJComparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasisAntimicrob Agents Chemother19974110208920929333030
   PubMedGoogle Scholar
• KataokaKHaradaANagasakiYBlock copolymer micelles for drug delivery: design, characterization and biological significanceAdv Drug Deliv Rev200147111313111251249
   PubMed Web of Science ®Google Scholar
• MendonçaDVCLageLMRLageDPPoloxamer 407 (Pluronic® F127)-based polymeric micelles for amphotericin B: in vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasisExp Parasitol2016169344227427166
   PubMed Web of Science ®Google Scholar
• BruguésAPNaverosBCCalpena CampmanyACPastorPHSaladrigasRFLizandraCRDeveloping cutaneous applications of paromomycin entrapped in stimuli-sensitive block copolymer nanogel dispersionsNanomedicine201510222724025600968
   PubMed Web of Science ®Google Scholar
• FernandesFRFerreiraWACamposMAAmphiphilic antimony(V) complexes for oral treatment of visceral leishmaniasisAntimicrob Agents Chemother20135794229423623796930
   PubMed Web of Science ®Google Scholar
• RibeiroRRFerreiraWAMartinsPSProlonged absorption of antimony(V) by the oral route from non-inclusion meglumine antimoniate-β-cyclodextrin conjugatesBiopharm Drug Dispos2010312–310911920014042
   PubMedGoogle Scholar
• Ali-BoucettaHKostarelosKCarbon nanotubes in medicine & biology – therapy and diagnosticsAdv Drug Deliv Rev201365151897189824220279
   PubMedGoogle Scholar
• BaezaAColillaMVallet-RegíMAdvances in mesoporous silica nanoparticles for targeted stimuli-responsive drug deliveryExpert Opin Drug Deliv201512231933725421898
   PubMed Web of Science ®Google Scholar
• AllahverdiyevAMAbamorESBagirovaMAntileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet lightInt J Nanomedicine201162705271422114501
   PubMed Web of Science ®Google Scholar
• JebaliAKazemiBNano-based antileishmanial agents: a toxicological study on nanoparticles for future treatment of cutaneous leishmaniasisToxicol In Vitro20132761896190423806227
   PubMed Web of Science ®Google Scholar
• SoflaeiSDalimiAAbdoliAAnti-leishmanial activities of selenium nanoparticles and selenium dioxide on Leishmania infantumComp Clin Pathol20142311520
   Google Scholar
• NadhmanANazirSKhanMIVisible-light-responsive ZnCuO nanoparticles: benign photodynamic killers of infectious protozoansInt J Nanomedicine2015106891690326604755
   PubMed Web of Science ®Google Scholar
• NadhmanANazirSIhsanullah KhanMPEGylated silver doped zinc oxide nanoparticles as novel photosensitizers for photodynamic therapy against LeishmaniaFree Radic Biol Med20147723023825266330
   PubMed Web of Science ®Google Scholar
• AhmadAWeiYSyedFIsatis tinctoria mediated synthesis of amphotericin B-bound silver nanoparticles with enhanced photoinduced antileishmanial activity: a novel green approachJ Photochem Photobiol B2016161172427203567
   PubMed Web of Science ®Google Scholar
• PrajapatiVKAwasthiKGautamSTargeted killing of Leishmania donovani in vivo and in vitro with amphotericin β attached to functionalized carbon nanotubesJ Antimicrob Chemother201166487487921393222
   PubMed Web of Science ®Google Scholar
• PrajapatiVKAwasthiKYadavTPRaiMSrivastavaONSundarSAn oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasisJ Infect Dis2012205233333622158723
   PubMed Web of Science ®Google Scholar
• KesterMHeakalYFoxTCalcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cellsNano Lett20088124116412119367878
   PubMed Web of Science ®Google Scholar
• ChenFZhuYWuJHuangPCuiDNanostructured calcium phosphates: preparation and their application in biomedicineNano Biomed Eng2012414149
   Google Scholar
• ChaurasiaMSinghPKJaiswalAKBioinspired calcium phosphate nanoparticles featuring as efficient carrier and prompter for macrophage intervention in experimental leishmaniasisPharm Res201633112617262927401407
   PubMed Web of Science ®Google Scholar
• AlvarengaBMMeloMNFrézardFNanoparticle phosphate-based composites as vehicles for antimony delivery to macrophages: possible use in leishmaniasisJ Mater Chem B201534892509259
   PubMedGoogle Scholar
• SinghJDesaiSYadavSNarasimhanBKaurHPolymer drug conjugates: recent advancements in various diseasesCurr Pharm Des201622192821284326898741
   PubMed Web of Science ®Google Scholar
• DuncanRPolymer therapeutics: top 10 selling pharmaceuticals – what next?J Control Release201419037138024818766
   PubMed Web of Science ®Google Scholar
• DuncanRVicentMJDo HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunitiesAdv Drug Deliv Rev201062227228220005271
   PubMed Web of Science ®Google Scholar
• NicolettiSSeifertKGilbertIHN-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agentsInt J Antimicrob Agents200933544144819097763
   PubMed Web of Science ®Google Scholar
• DosioFArpiccoSStellaBFattalEHyaluronic acid for anticancer drug and nucleic acid deliveryAdv Drug Deliv Rev20169720423626592477
   PubMed Web of Science ®Google Scholar
• MicaleNPipernoAMahfoudhNA hyaluronic acid-pentamidine bioconjugate as a macrophage mediated drug targeting delivery system for the treatment of leishmaniasisRSC Adv201551169554595550
   Google Scholar
• Le PapePDevelopment of new antileishmanial drugs – current knowledge and future prospectsJ Enzyme Inhib Med Chem200823570871818671165
   PubMed Web of Science ®Google Scholar
• MishraBBKaleRRSinghRKTiwariVKAlkaloids: future prospective to combat leishmaniasisFitoterapia2009802819019015012
   PubMed Web of Science ®Google Scholar
• EspuelasSPlanoDNguewaPInnovative lead compounds and formulation strategies as newer kinetoplastid therapiesCurr Med Chem201219254259428822834813
   PubMedGoogle Scholar
• PenãSScaroneLSerraGMacrocycles as potential therapeutic agents in neglected diseasesFuture Med Chem20157335538225650721
   PubMed Web of Science ®Google Scholar
• Castillo-GaritJAAbadCRodríguez-BorgesJEMarrero-PonceYTorrensFA review of QSAR studies to discover new drug-like compounds actives against leishmaniasis and trypanosomiasisCurr Top Med Chem201212885286522352913
   PubMedGoogle Scholar
• TariqAAdnanMAmberRPanKMussaratSShinwariZKEthnomedicines and anti-parasitic activities of Pakistani medicinal plants against Plasmodia and Leishmania parasitesAnn Clin Microbiol Antimicrob20161515227647140
   PubMedGoogle Scholar
• PolonioTEfferthTLeishmaniasis: drug resistance and natural products (review)Int J Mol Med200822327728618698485
   PubMed Web of Science ®Google Scholar
• NagleASKhareSKumarABRecent developments in drug discovery for leishmaniasis and human African trypanosomiasisChem Rev201411422113051134725365529
   PubMed Web of Science ®Google Scholar
• SangshettiJNKalam KhanFAKulkarniAAAroteRPatilRHAntileishmanial drug discovery: comprehensive review of the last 10 yearsRSC Adv20155413237632415
   Google Scholar
• MarrAKMcGwireBSMcMasterWRModes of action of leishmanicidal antimicrobial peptidesFuture Microbiol2012791047105922953706
   PubMed Web of Science ®Google Scholar
• SundarSChakravartyJInvestigational drugs for visceral leishmaniasisExpert Opin Investig Drugs20152414359
   PubMed Web of Science ®Google Scholar
• PenicheAGRensloARMelbyPCTraviBLAntileishmanial activity of disulfiram and thiuram disulfide analogs in an ex vivo model system is selectively enhanced by the addition of divalent metal ionsAntimicrob Agents Chemother201559106463647026239994
   PubMedGoogle Scholar
• FortinAHendrickxSYardleyVCosPJansenHMaesLEfficacy and tolerability of oleylphosphocholine (OLPC) in a laboratory model of visceral leishmaniasisJ Antimicrob Chemother201267112707271222782488
   PubMedGoogle Scholar
• HernándezLGálvezRMontoyaAFirst study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine – OlPC) in the treatment of canine leishmaniosis due to Leishmania infantumParasitol Res2014113115716424192865
   PubMedGoogle Scholar
• FortinADorloTPCHendrickxSMaesLPharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasisJ Antimicrob Chemother20167171892189827084920
   PubMedGoogle Scholar
• RoyPDasSBeraTMondolSMukherjeeAAndrographolide nanoparticles in leishmaniasis: characterization and in vitro evaluationsInt J Nanomedicine2010511113112121270962
   PubMedGoogle Scholar
• MondalSRoyPDasSHalderAMukherjeeABeraTIn Vitro susceptibilities of wild and drug resistant Leishmania donovani amastigote stages to andrographolide nanoparticle: role of vitamin e derivative TPGS for nanoparticle efficacyPLoS One2013812e8149224339938
   PubMedGoogle Scholar
• GhoshSKarNBeraTOleanolic acid loaded poly lactic co-glycolic acid-vitamin E TPGS nanoparticles for the treatment of Leishmania donovani infected visceral leishmaniasisInt J Biol Macromol20169396197027645930
   PubMed Web of Science ®Google Scholar
• TavaresJOuaissiASilvaAMLinPKTRoyNCordeiro-da-SilvaAAnti-leishmanial activity of the bisnaphthalimidopropyl derivativesParasitol Int201261236036322155672
   PubMedGoogle Scholar
• Costa LimaSAResendeMSilvestreRCharacterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studiesNanomedicine20127121839184922812711
   PubMed Web of Science ®Google Scholar
• YangDMLiewFYEffects of qinghaosu (artemisinin) and its derivatives on experimental cutaneous leishmaniasisParasitology199310617118479804
   PubMedGoogle Scholar
• WantMYIslamuddinMChouhanGDasguptaAKChattopadhyayAPAfrinFA new approach for the delivery of artemisinin: formulation, characterization, and ex-vivo antileishmanial studiesJ Colloid Interface Sci201443225826925086720
   PubMed Web of Science ®Google Scholar
• WantMYIslamuddinMChouhanGTherapeutic efficacy of artemisinin-loaded nanoparticles in experimental visceral leishmaniasisColloids Surf B Biointerfaces201513021522125936561
   PubMed Web of Science ®Google Scholar
• FouladvandMBarazeshATahmasebiREvaluation of in vitro antileishmanial activity of curcumin and its derivatives “Gallium curcumin, Indium curcumin and Diacethyle curcumin”Eur Rev Med Pharmacol Sci201317243306330824379060
   PubMed Web of Science ®Google Scholar
• CouvreurPStellaBHarivardhan ReddyLSqualenoyl nanomedicines as potential therapeuticsNano Lett20066112544254817090088
   PubMed Web of Science ®Google Scholar
• MaksimenkoADosioFMouginJA unique squalenoylated and nonpegylateddoxorubicin nanomedicine with systemiclong-circulating properties and anticancer activityProc Natl Acad Sci U S A20141112E217E22624385587
   PubMed Web of Science ®Google Scholar
• Cheikh-AliZCaronJCojeanS“Squalenoylcurcumin” nanoassemblies as water-dispersible drug candidates with antileishmanial activityChemMedChem201510241141825523035
   PubMed Web of Science ®Google Scholar
• TiwariBPahujaRKumarPRathSKGuptaKCGoyalNNanotized curcumin and miltefosine, a potential combination for treatment of experimental visceral leishmaniasisAntimicrob Agents Chemother2017613e011691628031196
   PubMed Web of Science ®Google Scholar
• PaloqueLVerhaeghePCasanovaMDiscovery of a new antileishmanial hit in 8-nitroquinoline seriesEur J Med Chem201254758622608675
   PubMedGoogle Scholar
• Costa DuarteMdos Reis LageLMLageDPAn effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasisVet Parasitol2016217818826827866
   PubMed Web of Science ®Google Scholar
• DuarteMCLageLMDRLageDPTreatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle systemParasitol Int201665672873627425599
   PubMedGoogle Scholar
• NanACroftSLYardleyVGhandehariHTargetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasisJ Control Release200494111512714684276
   PubMed Web of Science ®Google Scholar
• SaudagarPDubeyVKCarbon nanotube based betulin formulation shows better efficacy against Leishmania parasiteParasitol Int201463677277625086374
   PubMed Web of Science ®Google Scholar
• CrommelinDJAFlorenceATTowards more effective advanced drug delivery systemsInt J Pharm2013454149651123415662
   PubMedGoogle Scholar
• de MenezesJPGuedesCEPetersenALFragaDBVerasPSAdvances in development of new treatment for leishmaniasisBiomed Res Int2015201581502326078965
   PubMed Web of Science ®Google Scholar
• ZhangW-WLypaczewskiPMatlashewskiGOptimized CRISPR-Cas9 genome editing for Leishmania and its use to target a multigene family, induce chromosomal translocation, and study DNA break repair mechanismsmSphere201721e003401628124028
   PubMedGoogle Scholar
• AntillónADe VriesAHEspinosa-CaballeroMAn amphotericin B derivative equally potent to amphotericin B and with increased safetyPLoS One2016119e016217127683101
   PubMedGoogle Scholar
• OlliaroPLShamsuzzamanTAMarasiniBInvestments in research and surveillance are needed to go beyond elimination and stop transmission of Leishmania in the Indian subcontinentPLoS Negl Trop Dis2017111e000519028125596
   PubMedGoogle Scholar
• HiemenzJWWalshTJLipid formulations of amphotericin B: recent progress and future directionsClin Infect Dis199622suppl 2S133S1448722841
   PubMed Web of Science ®Google Scholar
• ThakurCPSinghRKHassanSMKumarRNarainSKumarAAmphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 casesTrans R Soc Trop Med Hyg199993331932310492770
   PubMed Web of Science ®Google Scholar
• Sánchez-BruneteJADeaMARamaSTreatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheresAntimicrob Agents Chemother20044893246325215328080
   PubMed Web of Science ®Google Scholar
• Sánchez-BruneteJADeaMARamaSInfluence of the vehicle on the properties and efficacy of microparticles containing amphotericin BJ Drug Target200513422523316051534
   PubMed Web of Science ®Google Scholar
• World Health OrganizationNeglected tropical diseases: WHO and Gilead Sciences extend collaboration against visceral leishma-niasis Available from: http://www.who.int/neglected_diseases/news/WHO_and_Gilead_Sciences_extend_collaboration/en/
   Google Scholar
• Drugs for Neglected Diseases InitiativeFexinidazole/Miltefosine combination (VL) Available from: https://www.dndi.org/diseases-projects/portfolio/completed-projects/fexinidazole-vl/
   Google Scholar
• iCo Therapeutics IncPipeline Available from: http://www.icothera-peutics.com/pipeline/
   Google Scholar
• Matinas BiopharmaLearn more about cochleate technology Available from: http://www.matinasbiopharma.com
   Google Scholar
• American Pharmaceutical ReviewFDA’s regulatory science program for generic PLA/PLGA-based drug products Available from: http://www.americanpharmaceuticalreview.com/Featured-Articles/188841-FDA-s-Regulatory-Science-Program-for-Generic-PLA-PLGA-Based-Drug-Products/
   Google Scholar